Pharma channel feed

Le­gal ex­perts say some IRA chal­lenges are 'weak­er than oth­er­s'

Last year
Law

Lil­ly, No­vo, Sanofi face pres­sure from law­mak­ers to clar­i­fy low-cost in­sulin pro­grams

Last year
FDA+

Alvotech re­sub­mits its in­ter­change­able Hu­mi­ra biosim­i­lar as Ab­b­Vie clings to brand dom­i­nance

Last year

Stop TB says the price of J&J's tu­ber­cu­lo­sis treat­ment be­daquiline drops 55%

Last year

Phar­ma in­dus­try rep­u­ta­tion set­tles in­to ‘new nor­mal’ af­ter good­will from in­sulin price drop fades

Last year
Marketing

Mallinck­rodt files for bank­rupt­cy for the sec­ond time, se­cures $150M to con­tin­ue op­er­at­ing

Last year

Sage re­mains tight-lipped on post­par­tum launch plans in wake of re­struc­tur­ing

Last year
People

Alk­er­mes, Te­va set­tle patent suit around opi­oid-block­er Viv­it­rol, paving way for gener­ics af­ter three-year fight

Last year
Law

Sanofi taps se­r­i­al biotech in­vestor, en­tre­pre­neur as R&D chief — while pro­mot­ing busi­ness op­er­a­tions, dig­i­tal lead­ers

Last year
People

Can­cer drugs in US are ‘not af­ford­able,’ says Ger­man study, which sug­gests set­ting drug prices by in­di­ca­tion 

Last year

In­cyte scores soc­cer star Mia Hamm as new spokesper­son to raise aware­ness of graft-ver­sus-host dis­ease

Last year
Marketing

The cost of We­govy: $1.1M to pre­vent one ma­jor car­dio­vas­cu­lar event, Airfin­i­ty says

Last year

Pfiz­er and BioN­Tech 'ready to ship' up­dat­ed Covid-19 vac­cine in EU on heels of CHMP rec­om­men­da­tion

Last year
Coronavirus

Lil­ly qui­et­ly com­pletes pur­chase of Pad­cev com­peti­tor, es­ti­mat­ed at near­ly half a bil­lion dol­lars

Last year
Startups
Deals

Sens. Durbin and Grass­ley lever­age Medicare drug ne­go­ti­a­tion list to rein­vig­o­rate a push for drug prices in ads

Last year
Marketing

De­mo­c­rat law­mak­ers call on FDA to take steps to pre­vent mis­use of Or­ange Book

Last year
FDA+

FDA+ roundup: FDA is­sues fi­nal guid­ance on use of re­al-world ev­i­dence

Last year
R&D
FDA+

FDA re­ject­ed Out­look Ther­a­peu­tic­s' Lu­cen­tis ri­val, and the com­pa­ny's stock plunged

Last year
FDA+

Bris­tol My­ers se­cures FDA la­bel ex­pan­sion for ane­mia drug Re­blozyl

Last year
FDA+

Great Britain ap­proves sub­cu­ta­neous Tecen­triq weeks ahead of ex­pect­ed US de­ci­sion

Last year
FDA+

Pfiz­er chal­lenges Mod­er­na Covid vac­cine patents be­fore Patent Tri­al and Ap­peal Board

Last year
Law

Mar­ket­ingRx roundup: Ar­cutis joins crowd­ed pso­ri­a­sis ad mar­ket on TV; Mer­ck, GSK, Mod­er­na high­light im­mu­niza­tion month

Last year
Marketing

Medicare's first drug ne­go­ti­a­tion list like­ly to fu­el pub­lic pric­ing dis­cus­sions for phar­ma mar­keters

Last year
Marketing

Apel­lis trims staff, shrinks R&D plans to save mon­ey in face of loom­ing com­pe­ti­tion in oph­thal­mol­o­gy

Last year
People
R&D
First page Previous page 103104105106107108109 Next page Last page
A service from the Financial Times